The American Journal of Sports Medicine published a long-form peptide primer this month aimed squarely at orthopedic and sports-medicine physicians, the surgeons whose patients most frequently arrive with questions about BPC-157 ↗, TB-500 ↗, and the rest of the injectable-peptide aisle of social media. The review's conclusion, summarized in the April 27 peptide news digest ↗, is consequential and should be on every sports-medicine reading list this quarter: preclinical evidence for tendon and muscle repair is real, but human evidence is essentially absent, and where it exists it is methodologically weak.
The most-cited human study for BPC-157, the peptide currently driving the largest share of patient demand, is a single twelve-patient case series. AJSM's authors flag significant methodological flaws in that study and note that no Phase 2 or Phase 3 trial has replaced it. TB-500 is in similar territory. Both peptides remain on the World Anti-Doping Agency banned list, which independently complicates any intent to study them in an athlete population.
The review's coverage extends beyond the two most-discussed compounds. CJC-1295 ↗ plus ipamorelin, a growth-hormone-releasing combination commonly sold for body composition. Tesamorelin ↗, the only FDA-approved analog of growth-hormone-releasing hormone, used in HIV-associated lipodystrophy. GHK-Cu ↗, the copper-binding tripeptide marketed for skin and wound healing. Each gets the same diagnosis: plausibility from preclinical data, no rigorous human trials at the doses and protocols actually being used.
Why this lands now matters. The Food and Drug Administration's Pharmacy Compounding Advisory Committee meets July 23-24 to decide whether BPC-157, TB-500, and several other peptides are added to the 503A bulks list, which would legalize their compounding under prescription. The AJSM review, plus a related qualitative study in Sports Health surveying Reddit user perspectives on post-surgery peptide use, plus the April update from the American Orthopaedic Society for Sports Medicine, signal that the orthopedic community is consolidating its position. The position is not "ban these molecules." The position is "we do not have human data, our patients are using them anyway, and any access decision should be paired with a research framework that gets data within the decade."
For a peptide-focused audience, the technical content of the review is also worth holding. BPC-157 in particular has been studied extensively in rodent tendon-repair models, where the effect sizes have been substantial. Whether tendon biology in a Sprague-Dawley rat translates to a torn supraspinatus in a fifty-year-old recreational tennis player is the question no one has answered. The peptide is also given empirically by patients in vials sourced from research-only suppliers, with no analytical certificate, no manufacturing standard, and no consistent batch testing. Even if the molecule works, the route to it does not.
The review does not call for the FDA to keep BPC-157 in Category 2. It calls for clinical infrastructure to actually study it. Those are different positions, and the difference matters in front of a public that has read three years of headlines suggesting peptides will do for tendons what semaglutide did for obesity. Peptides may. The clinical data set, today, does not say so.